NHS Suffolk Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and further notice)
|
|
- Emil Walton
- 8 years ago
- Views:
Transcription
1 NHS Suffolk Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and further notice) This drug has been reviewed because it is a product that may be prescribed in primary care. Medicine Fingolimod (Gilenya, Novartis) for relapsing - remitting multiple sclerosis (RRMS) Document status Considered at NHS Suffolk Drug and Therapeutics Committee meeting November 2010 Date of last revision 21st November 2010 Traffic light decision DOUBLE RED - Prescribing not supported in either general practice or secondary/tertiary care ( PENDING NICE) Prescribers rating Judgement reserved-the committee postpones its judgement until better data and a more thorough evaluation of the drug are available Mechanism of action Medicine class Indication Dosage Treatment alternatives Fingolimod, a novel drug, is an oral sphingosine-1-phosphate receptor modulator (S1P-R) modulator, which is thought to act therapeutically by retaining lymphocytes in the lymph nodes. This reduces infiltration of potentially auto-aggressive lymphocytes into the CNS where they could potentially attack the protective covering around the nerve fibres. (1,2) Other- immunomodulating drugs First line treatment for RRMS One 0.5mg capsule daily orally Current MS treatment consists of both symptomatic therapies which may or may not be licensed (e.g. steroids, baclofen and anti-cholinergics) as well as treatment with disease modifying therapies (DMTs) including beta-interferon 1a, glatiramer acetate, and natalizumab. Interferon beta and glatiramer are not currently recommended by NICE (TA32), but are available in the NHS through a Risk Sharing Scheme. (1) NICE recommends natalizumab as an option for the treatment only of rapidly evolving severe RRMS (TA 127). (3) Place in therapy Future alternatives All the DMTs currently are injectable / infusion products. First line oral therapy for RRMS; may be useful in patients with needle phobia or adverse effects to existing DMTs. Laquinimod, fampridine-sr and add-on therapies (to betainterferon alfa): teriflunamide, daclizumab (1) (NB: cladribine, another oral drug in the pipeline for MS was refused a marketing authorisation by the EMEA in September 2010 on safety grounds).
2 Evidence for use Key studies: for further detail please see appendix 1. The 2 fully published pivotal phase III trials are FREEDOMS (4) (placebo controlled) and TRANSFORMS (5) (head-to head study). Participants in the trials were adult patients with RRMS, aged under 56, with Expanded Disability Status Scale (EDSS, range 0-10, 10 worst) scores 0 to 5.5, and a history of one or more relapses in the previous year or two or more in the previous two years. Head-to-head trials of subcutaneous interferon beta-1b and interferon beta-1a vs. intramuscular interferon beta-1a showed advantages of both subcutaneous regimens over the latter. The interferon - beta 1a comparator in the TRANSFORMS trial was the intra-muscular regimen. More recent trials were unable to separate the clinical efficacy of the two subcutaneously administered forms of interferon beta from that of glatiramer acetate. FREEDOMS Trial (4) 24 month double-blind RCT (N=1,272) using oral fingolimod 0.5mg or 1.25mg daily vs. placebo. Median EDSS was 2 (range 0.5-5). Interferon-beta or glatiramer acetate therapy had to have been stopped three or more months before randomisation. The primary end point was the annualised relapse rate. To constitute a confirmed relapse, symptoms must have been accompanied by an increase of at least half a point in the EDSS score, of one point in each of two EDSS functional system scores, or of two points in one EDSS functional-system score (excluding scores for the bowel bladder or cerebral functional systems). Time to disability progression was a major secondary endpoint. In terms of the primary and secondary outcomes, fingolimod was superior to placebo with no significant difference between the two doses. Time to disability progression also favored fingolimod. Both fingolimod doses were superior to placebo with regard to MRI related measures. TRANSFORMS study (5) A second 12 month study (N=1,292) compared oral fingolimod with IM interferon beta-1a. Participants were similar to those in the placebo-controlled trial, and were randomised to oral
3 fingolimod 0.5mg or 1.25mg, or IM interferon beta-1a, 30mcg weekly. A double-blind, double-dummy design was used to retain blinding. Previous recent therapy with either any type of interferon beta or glatiramer acetate was not a criterion for exclusion. As with the placebo controlled study the primary end point was the annualised relapse rate, defined as the number of confirmed relapses per year. Major secondary outcomes were disability progression and new or enlarged hyper-intense lesions on T2-weighted MRI scans at 12 months. Primary and secondary outcomes favoured fingolimod. The authors conclude that fingolimod was superior to parenteral interferon beta-1a in the treatment of relapsing-remitting MS. NNT Cautions / side effects Critical Evaluation The patients in the trial populations did not have severe MS and were all fairly well. 14.2% of the trial population discontinued the drug when placed on higher doses. The interferon used in the comparator trials was the intramuscular (IM) whereas head to head trials of subcutaneous (SC) interferon-1b and interferon 1a showed advantages for both SC regimens over the IM form. NNT = 16 (for reduction in cumulative probability of disease progression (confirmed after 3 months) for the 0.5mg dose of fingolimod vs. placebo) Adverse events associated with fingolimod included bradycardia, hypertension and macular oedema. In the FREEDOMS trial, adverse events were similar in the three study groups, and most were mild to moderate in severity. Overall incidence of infection was similar across the three groups. (4) Adverse events were mild to moderate in severity in 82% of patients receiving 0.5 mg of fingolimod, 77% of those receiving 1.25 mg of fingolimod, and 77% of those receiving placebo. Serious adverse events were reported for 10.1% of patients receiving 0.5 mg of fingolimod, 11.9% of those receiving 1.25 mg of fingolimod, and 13.4% of those receiving placebo. Adverse events that led to discontinuation of the study medication (including abnormal laboratory test results) were more common with fingolimod at a dose of 1.25 mg (occurring in 14.2% of patients) than with fingolimod at a dose of 0.5 mg (occurring in 7.5%) or with placebo (occurring in 7.7%).
4 In the TRANSFORMS study the overall adverse event rates were similar in the three study groups, however serious adverse events were most common in the 1.25mg fingolimod group with two fatal herpes-virus infections occurring in this group. (5) The most common serious adverse events were bradycardia, multiple sclerosis relapse, and basal-cell carcinoma. All other serious adverse events occurred in four or fewer patients (<1%) in any study group. Bradycardia - monitoring is required as the heart rate will usually slow down the most 6 hours after the patient takes first dose. The seven episodes of bradycardia in the two fingolimod groups (three in the 0.5mg group and four in the 1.25mg group) were reported during the monitoring period after administration of the first dose. Five of these events were asymptomatic; the patients continued to receive fingolimod and the episodes were reported as serious adverse events because the protocol-defined discharge criteria for the first-dose monitoring period were not met. Macular oedema - seven patients in the 1.25mg group developed macular oedema during treatment; in six, this resolved after discontinuation. Respiratory and hepatic impairment. Herpes - the rate of herpes infections among patients receiving the 1.25mg dose of fingolimod was 5.5%; such infections were serious in three of these patients, two of whom died. Malignant neoplasms were reported in 4 patients receiving 0.5 mg of fingolimod, 4 receiving 1.25 mg of fingolimod, and 10 receiving placebo. All 11 skin cancers (basal-cell carcinoma, malignant melanoma, or Bowen s disease) that occurred (3 cases with 1.25-mg fingolimod, 4 with 0.5-mg fingolimod, and 4 with placebo) were removed successfully. Cost within PBR tariff? Cost (prices from MIMS Oct 2010) Comparative costs of other medicines Potential number of patients and usage within NHS Suffolk Likely excluded The costs of fingolimod tablets are not yet known. Main DMT alternatives (drug costs per patient Cost - ex VAT) (28 days) Beta-interferon (no administration costs as betainterferon is self-administered) Glatiramer acetate Natalizumab (for severe disease) (administration costs are an additional 8,379 per patient) Around 100,000 people in the UK have MS. (6) It is estimated that 15% of patients diagnosed with MS are
5 Points for consideration Is it on the WHS or IHT formularies? Decisions from other bodies Comments sought from Decision review date Jan 2013 eligible for a DMT of which 86% are likely to have RRMS. (7) Of 100,000 diagnosed patients = 15,000 patients will be eligible for treatment and 12,900 patients will have RRMS. In the UK 21 patients per 100,000 population may have a diagnosis of RRMS and eligible for treatment with fingolimod. Therefore within NHS Suffolk there may be patients with RRMS technically eligible for treatment with fingolimod although many of these patients may already be receiving a DMT for their MS. Some patients with RRMS and eligible for a DMT may not be receiving a DMT because of needle phobia or adverse effects to existing DMTs. Fingolimod is likely to marketed as a new and effective treatment option in MS which offers patients a convenient alternative to frequent injections. There were some severe adverse events noted in the trials. The most common serious adverse events were bradycardia, MS relapse, and basal-cell carcinoma. The rate of herpes infections among patients receiving the 1.25mg dose of fingolimod was 5.5%; such infections were serious in three of these patients, two of whom died. The trials reported that further follow-up is needed to clarify longer-term safety, including ophthalmic and cardiovascular effects, and the potential for herpesvirus reactivation. Fingolimod is an immunosuppressive drug. The Multiple Sclerosis Resource Centre has noted that the experimental drugs have serious side effects because they interfere with the body's immune system. (Note the EMEAs refusal to grant a marketing authorisation to cladribine on the grounds of safety). West Suffolk Hospital - no Ipswich Hospital - no Cambridgeshire JPG Double Red Norfolk TAG Not considered SMC - Not considered AWMSG Not considered NICE Appraisal in progress, draft TA guidance anticipated close to launch Q Consultant neurologists and specialists in MS; Dr Brierley, Lynette Baldwin, Dr Galton, Dr Graham, Dr Manji, Chris Boyes (Ipswich Hospital). Graham Lennox, Francesca Crawley, Dr Paul Molyneux, senior MS nurse, Mary Fraser (The West Suffolk Hospital)
6 This review is based on NHS Cambridgeshire s review (1) References 1. Cambridgeshire Joint Prescribing Group Submission considered March Available via _Decision_March_2010.sflb.ashx 2. Fingolimod. New Drugs Online report. Available via 3. Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis. NICE TA Kappos L, Radue E-W et al. A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis. New England Journal of Medicine 2010; 362: Cohen J, Barkhof F et al. Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis. (Editorial) New England Journal of Medicine 2010; 362: MS Society briefing on UK prevalence study issued June 2009 available via f3.pdf 7. Cost effective provision of disease modifying therapies for people with multiple sclerosis. HSC Available via statistics/lettersand circulars/healthservice circulars/dh_ Comments
7 Appendix 1 Key clinical trials Participants in the trials were adult patients with RRMS aged under 56, with Expanded disability Status Scale (EDSS, ranges 0 10, 10 worst) scores 0 to 5.5, and a history of one or more relapses in the previous year or two or more in the previous two years. Trial Study design as above Treatment Primary Endpoint Secondary Endpoints FREEDOMS (4) 24 month double-blind Total N=1,272 Time to disability progression RCT. (major secondary endpoint). Median Expanded Disability Status Scale (EDSS) was 2 (range 0-5.5). Interferon-beta or glatiramer acetate therapy had to have been stopped three or more months before randomisation. The main reasons for withdrawal were withdrawal of consent, adverse events (including abnormal laboratory tests) and lack of therapeutic effect. More patients withdrew for adverse events in the two fingolimod groups, and more for lack of effect in the placebo group. (1,033 completed the 24 months study) Oral fingolimod 0.5mg (N=425) or 1.25mg (N=429) daily vs. placebo (N=418) The primary end point was the annualised relapse rate. To constitute a confirmed relapse, symptoms must have been accompanied by an increase of at least half a point in the EDSS score, of one point in each of two EDSS functional system scores, or of two points in one EDSS functionalsystem score (excluding scores for the bowel bladder or cerebral functional systems). Fingolimod was superior to placebo with no significant difference between the two doses Annualised relapse rate was 0.18 and 0.16 with 0.5 mg and 1.25mg of fingolimod respectively, and 0.40 with placebo (p<0.001 for either dose vs. placebo). Time to disability progression favored fingolimod; for example risk of disability progression over 24 months (hazard ratio, 0.70 and 0.68, for 0.5mg and 1.25mg respectively; p=0.02 vs. placebo, for both comparisons). The cumulative probability of disability progression (confirmed after 3 months) was 17.7% with 0.5 mg of fingolimod, 16.6% with 1.25 mg of fingolimod, and 24.1% with placebo. Both fingolimod doses were superior to placebo with regard to MRI related measures (number of new or enlarged lesions on T2 - weighted images, gadoliniumenhancing lesions, and brainvolume loss; p<0.001 for all comparisons at 24 months).
8 TRANSFORMS (5) 12 months study randomised, doubleblind, double-dummy (used to retain blinding). Participants were similar to those in the placebocontrolled trial, Previous recent therapy with either any type of interferon beta or glatiramer acetate was not a criterion for exclusion. The most frequent reasons for withdrawal were adverse events and withdrawal of consent. Total N=1,292 (1,153 completed the study) oral fingolimod 0.5mg (N=431) or 1.25mg (N=426), or IM interferon beta-1a, 30 mcg (N=435) weekly. The primary end point was the annualised relapse rate, defined as the number of confirmed relapses per year. Potential relapses triggered an unscheduled visit and were confirmed by the treating neurologists on the basis of blinded examination by the examining neurologist. Relapse was defined as new, worsening, or recurrent neurological symptoms that occurred at least 30 days after the onset of a preceding relapse, that lasted at least 24 hours without fever or infection, and that were accompanied by an increase of at least half a point on the EDSS or an increase of at least one point in two functional-systems scores or of at least two points in one functional-system score (excluding changes in bowel or bladder function and cognition). Major secondary outcomes were disability progression and new or enlarged hyper-intense lesions on T2-weighted MRI scans at 12 months. Secondary outcomes also favoured fingolimod. The annualised rate of relapse was 0.20 (95% CI, 0.16 to 0.26) in the 1.25-mg group, and 0.16 (95% CI, 0.12 to 0.21) in the 0.5- mg group vs (95% CI, 0.26 to 0.42) in the interferon group (p<0.001 for both comparisons).
9 Grids used to assist the NHS Suffolk PCT Drug & Therapeutics Committee in reaching a decision about new medications For many years scientists have recognised two types of research: Primary: original studies, based on observation or experimentation on subjects. Secondary: reviews of published research, drawing together the findings of two or more primary studies. In biomedical science there is general agreement over a hierarchy: the higher up a methodology is ranked, the more robust and closer to objective truth it is assumed to be. The orthodox hierarchy looks something like this; Rank: Methodology Description 1 Systematic reviews and meta-analyses Systematic review: review of a body of data that uses explicit methods to locate primary studies, and explicit criteria to assess their quality. Meta-analysis: A statistical analysis that combines or integrates the results of several independent clinical trials considered by the analyst to be "combinable" usually to the level of re-analysing the original data, also sometimes called: pooling, quantitative synthesis. Both are sometimes called "overviews." 2 Randomised controlled trials (finer distinctions may be drawn within this group based on statistical parameters like the confidence intervals) Individuals are randomly allocated to a control group and a group who receive a specific intervention. Otherwise the two groups are identical for any significant variables. They are followed up for specific end points.
10 3 Cohort studies Groups of people are selected on the basis of their exposure to a particular agent and followed up for specific outcomes. 4 Case-control studies "Cases" with the condition are matched with "controls" without, and a retrospective analysis used to look for differences between the two groups. 5 Cross sectional surveys Survey or interview of a sample of the population of interest at one point in time 6 Case reports. A report based on a single patient or subject; sometimes collected together into a short series 7 Expert opinion A consensus of experience from the good and the great. 8 Anecdotal Something a bloke told you after a meeting or in the bar. Adapted from Systematic reviews, What are they and why are they useful? ScHARR 2008
11 To Decide if a Medication Is To Be Used In Suffolk Criterion to be measured Tends to poor 2 Medium 4 Tends to good Quality of evidence in the papers reviewed Magnitude of effect inferred from trials reviewed Low Medium High Are trial end-points surrogate markers or clinical outcomes? Clinical outcomes Clinical usefulness of trial end-points x Known Side Effect Profile High Medium Low Known Interactions High Medium Low Concern re Possible Side Effects Not Yet Uncovered High Medium Low Balance of Benefit To Harm (side effects toxicity interactions etc) Poor Medium Good NNT High Medium X Low Comparison Of Effectiveness With Other Medicines In Use For The Same Condition Poor Medium X Good
12 Severity of Condition to be Treated Trivial Medium x Severe Novel drug or member of existing class Novel Uptake (estimated proportion of people with this condition likely to be prescribed the medication under consideration maximum and minimum uptake) 60 to 70 patients Prescriber s Rating Definitions Bravo! -The drug is a major therapeutic advance in an area where previously no treatment was available. A real advance - The product is an important therapeutic innovation but has certain limitations. Offers an advantage - The product has some value but does not fundamentally change present therapeutic practice. Possibly Helpful - The product has minimal additional value, and should not change prescribing habits except in rare circumstances. Judgement reserved - The Committee postpones its judgement until better data and a more thorough evaluation of the drug are available. Nothing New - The product may be a new substance but is superfluous because it does not add to the clinical possibilities offered by previous products available. In most cases these are me-too products. Not acceptable - Product without evident benefit over others but with potential or real disadvantages. (With acknowledgement to Prescrire) To Decide Where A Medication Is To Be Used In Suffolk
13 Skills of the prescriber Criterion Red Amber Green Blue Experience Of The Condition Specific Specific Specific General Diagnosis Specific Specific Specific General Monitoring Progress Of Treatment Difficult Specific General General Therapy Patient Selection Difficult Specific Specific Easy Initiation Of Treatment Difficult Difficult Easy Easy Dose Titration Difficult Specific Easy Easy Monitoring Of Side Effects Complex Easy Easy Easy Method Of Administration Complex Normal Normal Normal Discontinuation Of Treatment Complex Complex Easy Easy References Jonsen A. Bentham in a box: Technology assessment and health care allocation. Law Med. Health Care. 1986;14: Suffolk Drug & Therapeutics Committee Responsibility for prescribing, Hospital Trust or GP Attached as Appendix 1 and Appendix 2
Version History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author
Version History Policy Title Drugs for MS.Drug facts box fingolimod Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields as required
More informationfingolimod, 0.5mg, hard capsules (Gilenya ) SMC No. (992/14) Novartis Pharmaceuticals UK
fingolimod, 0.5mg, hard capsules (Gilenya ) SMC No. (992/14) Novartis Pharmaceuticals UK 08 August 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises
More informationVersion History. Previous Versions. for secondary progressive MS (SPMS) Policy Title. Drugs for MS.Drug facts box Interferon beta 1b
Version History Policy Title Drugs for MS.Drug facts box Interferon beta 1b for secondary progressive MS (SPMS) Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January
More informationfingolimod (as hydrochloride), 0.5mg hard capsules (Gilenya ) SMC No. (763/12) Novartis Pharmaceuticals UK Ltd
fingolimod (as hydrochloride), 0.5mg hard capsules (Gilenya ) SMC No. (763/12) Novartis Pharmaceuticals UK Ltd 10 February 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationVersion History. Previous Versions. Policy Title. Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author
Version History Policy Title Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields
More informationDepartment of Health. Rheynn Slaynt. Clinical Recommendations Committee
Recommendation 06/13 Department of Health Rheynn Slaynt Clinical Recommendations Committee The Isle of Man Department of Health recommend Gilenya (fingolimod) as a HIGH PRIORITY - as an option for the
More informationClinical Commissioning Policy: Disease Modifying Therapies For patients With Multiple Sclerosis (MS) December 2012. Reference : NHSCB/D4/c/1
Clinical Commissioning Policy: Disease Modifying Therapies For patients With Multiple Sclerosis (MS) December 2012 Reference : NHSCB/D4/c/1 NHS Commissioning Board Clinical Commissioning Policy: Disease
More informationNew and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents
New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents William Tyor, M.D. Chief, Neurology Atlanta VA Medical Center Professor, Department of Neurology Emory University School of Medicine
More informationNHS BOURNEMOUTH AND POOLE AND NHS DORSET
NHS BOURNEMOUTH AND POOLE AND NHS DORSET COMMISSIONING STATEMENT ON THE USE OF BETA-INTERFERON IN RELAPSING-REMITTING MULTIPLE SCLEROSIS OR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, WHERE RELAPSES ARE
More informationMedication Policy Manual. Topic: Gilenya, fingolimod Date of Origin: November 22, 2010
Medication Policy Manual Policy No: dru229 Topic: Gilenya, fingolimod Date of Origin: November 22, 2010 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January
More informationHow To Use A Drug In Multiple Sclerosis
Revised (2009) guidelines for prescribing in multiple sclerosis INTRODUCTION In January 2001, the (ABN) first published guidelines for the use of licensed disease modifying treatments (ß-interferon and
More informationteriflunomide, 14mg, film-coated tablets (Aubagio ) SMC No. (940/14) Genzyme Ltd.
teriflunomide, 14mg, film-coated tablets (Aubagio ) SMC No. (940/14) Genzyme Ltd. 10 January 2014 (Issued 07 February 2014) The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationCommittee Approval Date: December 12, 2014 Next Review Date: December 2015
Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Daclizumab for treating relapsing-remitting multiple Draft scope (pre-referral) Draft remit/appraisal objective To
More informationThe submission positioned dimethyl fumarate as a first-line treatment option.
Product: Dimethyl Fumarate, capsules, 120 mg and 240 mg, Tecfidera Sponsor: Biogen Idec Australia Pty Ltd Date of PBAC Consideration: July 2013 1. Purpose of Application The major submission sought an
More informationRelapsing-remitting multiple sclerosis Ambulatory with or without aid
AVONEX/BETASERON/COPAXONE/EXTAVIA/GILENYA/REBIF/TYSABRI Applicant must be covered on an Alberta Government sponsored drug program. Page 1 of 5 PATIENT INFMATION Surname First Name Middle Initial Sex Date
More information1. Comparative effectiveness of alemtuzumab
Cost-effectiveness of alemtuzumab (Lemtrada ) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease defined by clinical or imaging features The NCPE has issued
More informationEngland XXXX 2013 Reference: NHS ENGLAND XXX/X/X
Clinical Commissioning Policy: Policy: Disease Modifying Therapies for Disease Patients Modifying with Multiple Therapies Sclerosis for Patients (MS) with Multiple Sclerosis (MS) May 2014 May Reference:
More informationTeriflunomide for treating relapsing remitting multiple sclerosis
Teriflunomide for treating relapsing remitting multiple Issued: January 2014 last modified: June 2014 guidance.nice.org.uk/ta NICE has accredited the process used by the Centre for Health Technology Evaluation
More informationA neurologist would assess your eligibility and suitability for the DMTs.
Choices Disease Modifying Treatments Disease modifying treatments (DMTs) are medications which modify the disease course. They target inflammation and are designed to reduce the damage caused by relapses.
More informationDisease Modifying Therapies for MS
Disease Modifying Therapies for MS The term disease-modifying therapy (DMT) means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks
More informationSECTION 2. Section 2 Multiple Sclerosis (MS) Drug Coverage
SECTION 2 Multiple Sclerosis (MS) Drug Coverage Section 2 Multiple Sclerosis (MS) Drug Coverage ALBERTA HEALTH AND WELLNESS DRUG BENEFIT LIST Selected Drug Products used in the treatment of patients with
More informationCost-effectiveness of teriflunomide (Aubagio ) for the treatment of adult patients with relapsing remitting multiple sclerosis
Cost-effectiveness of teriflunomide (Aubagio ) for the treatment of adult patients with relapsing remitting multiple sclerosis The NCPE has issued a recommendation regarding the cost-effectiveness of teriflunomide
More informationpeginterferon 63, 94 and 125 microgram solution for injection in pre-filled syringe (Plegridy ) SMC No. (1018/14) Biogen Idec Ltd.
peginterferon 63, 94 and 125 microgram solution for injection in pre-filled syringe (Plegridy ) SMC No. (1018/14) Biogen Idec Ltd. 05 December 2014 The Scottish Medicines Consortium (SMC) has completed
More informationNews on modifying diseases therapies. Michel CLANET CHU Toulouse France ECTRIMS
News on modifying diseases therapies Michel CLANET CHU Toulouse France ECTRIMS Current treatment strategies Future oral treatments Future non oral treatments Drug safety and risks CIS at risk of MS Active
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Gold R, Giovannoni G, Selmaj K, et al, for
More informationTreatment guidelines for relapsing MS and the two step approach for disease modifying therapy
Treatment guidelines for relapsing MS and the two step approach for disease modifying therapy Klaus Schmierer, PhD FRCP Blizard Institute, Barts and The London School of Medicine & Dentistry Barts Health
More informationIntegrating New Treatments: A Case Based Approach
Integrating New Treatments: A Case Based Approach JILL CONWAY, MD, MA, MSCE DIRECTOR, MS CENTER DIRECTOR, NEUROLOGY CLERKSHIP AT UNCSOM- CHARLOTTE CAMPUS CAROLINAS HEALTHCARE CENTER Objectives Provide
More informationMultiple Sclerosis (MS) Class Update
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Multiple Sclerosis (MS) Class Update Month/Year of
More informationMedication Policy Manual. Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014
Medication Policy Manual Policy No: dru376 Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective
More informationWhich injectable medication should I take for relapsing-remitting multiple sclerosis?
Which injectable medication should I take for relapsing-remitting multiple sclerosis? A decision aid to discuss options with your doctor This decision aid is for you if you: Have multiple sclerosis Have
More informationAlemtuzumab for treating relapsing-remitting multiple sclerosis
Alemtuzumab for treating relapsing-remitting multiple Issued: May 2014 guidance.nice.org.uk/ta NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE to produce technology
More informationDisease Modifying Therapies for MS
Disease Modifying Therapies for MS The term disease-modifying therapy means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks
More informationTwo-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis
Your contact News Release Barbara Fry Phone +1 905 919 0163 April 29/30, 2009 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple
More informationProgress in MS: Current and Emerging Therapies
Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC The MS Society gratefully acknowledges the grant received from Biogen Idec Canada, which makes possible the
More informationPersonalised Medicine in MS
Personalised Medicine in MS Supportive Evidence from Therapeutic Trials Ludwig Kappos Neurology and Department of Biomedicine University Hospital CH-4031 Basel LKappos@uhbs.ch Established partially effective
More informationDimethyl fumarate for treating relapsing remitting multiple sclerosis
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Final appraisal determination Dimethyl fumarate for treating relapsing remitting multiple sclerosis This guidance was developed using the single technology
More informationMSTAC Initial Application
MSTAC Initial Application Please send applications to: Facsimile 04 916 7571 Further Contact Details: Address The Co-ordinator MSTAC PHARMAC P O Box 10-254 WELLINGTON Phone 04 460 4990 Email mstaccoordinator@pharmac.govt.nz
More informationSummary HTA. Interferons and Natalizumab for Multiple Sclerosis Clar C, Velasco-Garrido M, Gericke C. HTA-Report Summary
Summary HTA HTA-Report Summary Interferons and Natalizumab for Multiple Sclerosis Clar C, Velasco-Garrido M, Gericke C Health policy background Multiple sclerosis (MS) is a chronic inflammatory disease
More informationalemtuzumab, 12mg, concentrate for solution for infusion (Lemtrada ) SMC No. (959/14) Genzyme
alemtuzumab, 12mg, concentrate for solution for infusion (Lemtrada ) SMC No. (959/14) Genzyme 04 April 2014 (Issued 06 June 2014) The Scottish Medicines Consortium (SMC) has completed its assessment of
More informationDisclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
More informationLaquinimod Polman, C. et al. Neurology 2005;64:987-991
Laquinimod Polman, C. et al. Neurology 2005;64:987-991 Multicenter, double-blind, randomized trial, patients with RR MS received 0.1 mg or 0.3 mg laquinimod or placebo as three daily tablets for 24 weeks
More informationNew treatments in MS What s here and what s nearly here
5 th MS Research Day, June 14 th 2014 New treatments in MS What s here and what s nearly here David Miller Queen Square MS Centre at UCL and UCLH Course of MS and its treatment Relapsing remitting Disability
More informationCost-effectiveness of dimethyl fumarate (Tecfidera ) for the treatment of adult patients with relapsing remitting multiple sclerosis
Cost-effectiveness of dimethyl fumarate (Tecfidera ) for the treatment of adult patients with relapsing remitting multiple sclerosis The NCPE has issued a recommendation regarding the cost-effectiveness
More informationß-interferon and. ABN Guidelines for 2007 Treatment of Multiple Sclerosis with. Glatiramer Acetate
ABN Guidelines for 2007 Treatment of Multiple Sclerosis with ß-interferon and Glatiramer Acetate Published by the Association of British Neurologists Ormond House, 27 Boswell Street, London WC1N 3JZ Contents
More informationEconomic Evaluation of Natalizumab (Tysabri) for the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or
Economic Evaluation of Natalizumab (Tysabri) for the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or sub-optimally treated Summary In January 2007 Biogen Idec
More informationDimethyl fumarate for treating relapsing-remitting multiple sclerosis
Dimethyl fumarate for treating relapsing-remitting multiple Issued: August 2014 guidance.nice.org.uk/ta320 NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE to
More informationUnderstanding How Existing and Emerging MS Therapies Work
Understanding How Existing and Emerging MS Therapies Work This is a promising and hopeful time in the field of multiple sclerosis (MS). Many new and different therapies are nearing the final stages of
More informationAlemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Appendix D
Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis Appendix D Response to consultee and commentator comments on the draft remit and draft scope & Response to consultee and commentator
More informationacquired chronic immune-mediated inflammatory condition of CNS. MS in children: 10% +secondary progressive MS: rare +primary progressive MS: rare
Immunomodulatory Therapies in Pediatric MS Vuong Chinh Quyen Neurology Department Medscape Mar 8, 2013 Multiple Sclerosis in Children. Iran J Child Neurol. 2013 Spring Introduction acquired chronic immune-mediated
More informationCommissioning Policy: Disease Modifying Therapies for patients with Multiple Sclerosis (MS).
Commissioning Policy: Disease Modifying Therapies for patients with Multiple Sclerosis (MS). Reference No: Version: 1 Ratified by: EMSCGP029V1 EMSCG Board Date ratified: 25/09/2009 Name of originator/author:
More informationIssues Regarding Use of Placebo in MS Drug Trials. Peter Scott Chin, MD Novartis Pharmaceuticals Corporation
Issues Regarding Use of Placebo in MS Drug Trials Peter Scott Chin, MD Novartis Pharmaceuticals Corporation Context of the Guidance The draft EMA Guidance mentions placebo as a comparator for superiority
More informationConflict of Interest Declaration. Overview of New Medications for Multiple Sclerosis. Assessment Question. Objectives 4/1/2011
Conflict of Interest Declaration Overview of New Medications for Multiple Sclerosis I or my spouse have no actual or potential conflict of interest in relation to this activity. Crystal Obering, Pharm.D.,
More informationNatalizumab (Tysabri)
Natalizumab (Tysabri) Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 Natalizumab (Tysabri) Date of issue: July 2010 Review date: July 2011 Contents Section
More informationLiterature Scan: Oral Multiple Sclerosis Drugs
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationDrug Class Review. Disease-modifying Drugs for Multiple Sclerosis. Single Drug Addendum: Fingolimod
Drug Class Review Disease-modifying Drugs for Multiple Sclerosis Single Drug Addendum: Fingolimod Final Original Report February 2011 The Agency for Healthcare Research and Quality has not yet seen or
More informationReview Date: March 2012. Issue Status: Approved Issue No: 2 Issue Date: March 2010
Title: Multiple Sclerosis guidelines for the use of beta-interferon, glatiramer acetate, natalizumab, mitoxantrone and other disease Authors Name: Dr P Talbot Contact Name: Dr Paul Talbot Contact Phone
More informationChapter 10. Summary & Future perspectives
Summary & Future perspectives 123 Multiple sclerosis is a chronic disorder of the central nervous system, characterized by inflammation and axonal degeneration. All current therapies modulate the peripheral
More informationManaging Relapsing Remitting MS Risks & benefits of emerging therapies. Dr Mike Boggild The Walton Centre
Managing Relapsing Remitting MS Risks & benefits of emerging therapies Dr Mike Boggild The Walton Centre MS: Facts and figures Affects 1 in 800 in the UK Commonest cause of acquired neurological disability
More informationEvidence Review Group s Report Template This template should be completed with reference to NICEs Guide to the Methods of Single Technology Appraisal
Evidence Review Group s Report Template This template should be completed with reference to NICEs Guide to the Methods of Single Technology Appraisal Title: Fingolimod for the treatment of relapsing remitting
More informationPCORI Workshop on Treatment for Multiple Sclerosis. Breakout Group Topics and Questions Draft 3-27-15
PCORI Workshop on Treatment for Multiple Sclerosis Breakout Group Topics and Questions Draft 3-27-15 Group 1 - Comparison across DMTs, including differential effects in subgroups Consolidated straw man
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
More informationNatalizumab for the treatment of adults with highly active relapsing remitting multiple sclerosis
Natalizumab for the treatment of adults with highly active relapsing remitting multiple sclerosis Premeeting briefing This briefing presents major issues arising from the manufacturer s submission, Evidence
More informationboceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationCase Report Early Bilateral Cystoid Macular Oedema Secondary to Fingolimod in Multiple Sclerosis
Case Reports in Medicine Volume 2012, Article ID 134636, 4 pages doi:10.1155/2012/134636 Case Report Early Bilateral Cystoid Macular Oedema Secondary to Fingolimod in Multiple Sclerosis Lei Liu and Fiona
More informationImmunex Corporation Novantrone (Mitoxantrone HCL) P&CNS Advisory Committee Briefing Document. Page 020
Page 020 4.0 Efficacy of Mitoxantrone in Multiple Sclerosis The efficacy of mitoxantrone in MS was demonstrated in two well-designed, randomized trials: Studies 901 and 902. The study design and efficacy
More informationMS Society response to the NICE Appraisal Consultation Document (ACD) on Fingolimod
MS Society response to the NICE Appraisal Consultation Document (ACD) on Fingolimod About the MS Society Established in 1953 and with over 38,000 members and 290 branches, the MS Society is the UK s largest
More informationGrowth in revenue from MS drugs has been driven largely by price increases over the last several years.
March 4, 2013 Ben Weintraub, PhD Are Injectable MS Drugs Finished? Market Ready for Tecfidera Companies: Biogen (BIIB) Sanofi (SNY) Teva (TEVA) Novartis (NVS) Merck Serono Bayer Schering Products: Tecfidera
More informationFingolimod (Gilenya ) National Drug Monograph
Fingolimod (Gilenya ) National Drug Monograph February 211 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives The purpose of VA PBM Services drug monographs
More informationMedication Policy Manual. Topic: Betaseron, Extavia, interferon beta-1b Date of Origin: June 18, 2004
Medication Policy Manual Policy No: dru108 Topic: Betaseron, Extavia, interferon beta-1b Date of Origin: June 18, 2004 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective
More informationSupplementary webappendix
Supplementary webappendix This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Giovannoni G, Gold R, Selmaj K, et al,
More informationPatients with confirmed relapse 111 26 (23.4 %) 104 16 (15.4 %) 1.52 [0.87; 2.67] p = 0.143 Probability of a relapse by week 96
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in
More informationA blood sample will be collected annually for up to 2 years for JCV antibody testing.
Mellen Center Currently Enrolling Non-Treatment Trials STRATIFY-2 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri Primary Investigator:
More informationDrug Class Review Disease-modifying Drugs for Multiple Sclerosis
Drug Class Review Disease-modifying Drugs for Multiple Sclerosis Final Update 3 Report May 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness
More informationMultiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON
Multiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON First-line DMTs Reduce Relapse Frequency by ~30% vs. Placebo Frequency of relapse with various DMTs, based
More informationNational MS Society Information Sourcebook www.nationalmssociety.org/sourcebook
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Chemotherapy The literal meaning of the term chemotherapy is to treat with a chemical agent, but the term generally refers
More information- Patients treated with alemtuzumab in CARE-MS II were more than twice as likely to experience disability improvement compared to Rebif -
PRESS RELEASE Significant Improvement in Disability Scores Observed in Multiple Sclerosis Patients Who Received Lemtrada TM* (Alemtuzumab) Compared With Rebif in Phase lll Trial - Patients treated with
More informationUpdates to the Alberta Human Services Drug Benefit Supplement
Updates to the Alberta Human Services Drug Benefit Supplement Effective December 1, 2014 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone
More informationLemtrada (alemtuzumab)
Lemtrada (alemtuzumab) Policy Number: 5.02.517 Last Review: 08/2015 Origination: 08/2015 Next Review: 08/2016 Policy BCBSKC will provide coverage for Lemtrada (alemtuzumab) when it is determined to be
More informationOriginal Policy Date
MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer
More informationMultiple Sclerosis - Relapsing and Remissioning
DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS* Benjamin M. Greenberg, MD, MHS ABSTRACT Four major disease-modifying therapies are discussed within the context of relapsing and remitting
More informationTeriflunomide (Aubagio)
Teriflunomide (Aubagio) Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 We hope you find the information in this factsheet helpful. If you would like to speak
More informationHow to S.E.A.R.C.H. SM for the Right MS Therapy For You!
How to S.E.A.R.C.H. SM for the Right MS Therapy For You! The Changing Landscape The first treatment for relapsing-remitting multiple sclerosis (RRMS) was approved by the United States Food and Drug Administration
More informationSuffolk PCT Drug & Therapeutics Committee New Medicine Report
Suffolk PCT Drug & Therapeutics Committee New Medicine Report This drug has been reviewed because it is a product that may be prescribed in primary care. Medicine Fesoterodine (Toviaz, Pfizer) Document
More informationNovel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS?
Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS? Marie Trad, M.D., Lynne Hughes, Cathy VanBelle, Amy Del Medico 3rd International
More informationRecruitment Start date: April 2010 End date: Recruitment will continue until enrolment is fully completed
Apitope study The study drug (ATX-MS-1467) is a new investigational drug being tested as a potential treatment for relapsing forms of multiple sclerosis (RMS). The term investigational drug means it has
More informationboceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationMultiple Sclerosis in Practice. An Expert Commentary With Jeffrey Cohen, MD, PhD A Clinical Context Report
Multiple Sclerosis in Practice An Expert Commentary With Jeffrey Cohen, MD, PhD A Clinical Context Report Clinical Context: Multiple Sclerosis in Practice Expert Commentary Jointly Sponsored by: and Clinical
More informationHas the medication received FDA approval? Yes the FDA approved dimethyl fumarate on March 27, 2013.
Dimethyl Fumarate [formerly called BG-12] (Tecfidera ) CLINICIAN INFORMATION What is the medication? April 2013 Generic: Dimethyl Fumarate [formerly called BG-12] Brand name: Tecfidera The third oral medication
More informationPerformance Improvement Strategies in Multiple Sclerosis. Community of Practice Audioconference Recorded December 7, 2010
Performance Improvement Strategies in Multiple Sclerosis Community of Practice Audioconference Recorded December 7, 2010 Audioconference faculty: Bruce A. Cohen, MD Director, Multiple Sclerosis Program
More informationGilenya. Exceptional healthcare, personally delivered
Gilenya Exceptional healthcare, personally delivered Your Consultant Neurologist has suggested that you may benefit from treatment with Gilenya. The decision to start this form of treatment can be difficult.
More informationMultiple Sclerosis Drug Discoveries - What the Future Holds
Brochure More information from http://www.researchandmarkets.com/reports/1408035/ Multiple Sclerosis Drug Discoveries - What the Future Holds Description: The recent approval in the US of Novartis' orally
More informationDisease modifying drug therapy
Disease modifying drug therapy what you need to know Third Edition Karen Alldus Simon Webster SECTION 2 We hope you find the information in this book helpful. If you would like to speak with someone about
More informationHealth Service Circular
Health Service Circular Series Number: HSC 2002/004 Issue Date: 04 February 2002 Review Date: 04 February 2005 Category: General Health Service Status: Action sets out a specific action on the part of
More informationDrug Use Research & Management Program Phone Fax Generic Name: Brand Name (Manufacturer): PDL Class: Comparator Therapies: Dossier received:
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Generic Name: Fingolimod Brand Name (Manufacturer):
More informationResources for the Primary Care Provider. Please print these out for reference
Resources for the Primary Care Provider Please print these out for reference Resources for providers American Academy of Neurology www.aan.com Provides education and resources, such as guidelines for clinical
More informationEverolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line
More informationDecisions relating to Multiple Sclerosis treatments
10 October 2014 Decisions relating to Multiple Sclerosis treatments PHARMAC is pleased to announce that, from 1 November 2014, it will: list fingolimod (Gilenya); list natalizumab (Tysabri); and change
More information